Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use CIBINQO safely and effectively. See full prescribing information for CIBINQO. CIBINQO® (abrocitinib) tablets, for oral use Initial U.S. Approval: 2022
Medication labelWhy this: Advisory · dailymed-prescription
CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable. Limitations of Use CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.
- generic_name
- abrocitinib
- product_names
- abrocitinib
- ndc
- 0069-0235, 0069-0335, 0069-0435, 0069-0235-30, 0069-0335-30, 0069-0435-30
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en